Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

9

Revenue 2014

Gilead Sciences

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Gilead Sciences' 2013 sales performance.

Gilead Sciences promotes Dr Alessandro Riva to EVP, oncology therapeutics

Gilead Sciences promotes Dr Alessandro Riva to EVP, oncology therapeutics

Gilead Sciences promotes Dr Alessandro Riva to EVP, oncology therapeutics. He's been with the firm since January, when he joined from Novartis. ... Gilead Sciences has promoted Dr Alessandro River from senior vice president, haematology and oncology

Kite wins FDA approval for blood cancer drug Yescarta

Kite wins FDA approval for blood cancer drug Yescarta John Milligan, president and chief executive officer of Gilead Sciences, said: “It’s an important day for patients with relapsed or refractory large B-cell lymphoma who have run out of ... With the combined innovation, talent and drive of the Kite

Merck & Co pulls out of hepatitis C R&D as market shrinks

Merck & Co pulls out of hepatitis C R&D as market shrinks And in the interim, the drugs used to treat HCV have largely been produced by Gilead Sciences, with AbbVie and Merck jostling for a distant second place. ... Now, with Gilead and AbbVie reporting shrinking sales and Johnson &Johnson (J&J) deciding it is

Merck pulls out of hepatitis C R&D as market shrinks

Merck pulls out of hepatitis C R&D as market shrinks And in the interim, the drugs used to treat HCV have largely been produced by Gilead Sciences, with AbbVie and Merck jostling for a distant second place. ... Now, with Gilead and AbbVie reporting shrinking sales and Johnson &Johnson (J&J) deciding it is

Pharma deals continue to slide

Pharma deals continue to slide Given big pharma’s reluctance to spend on M&A it is perhaps surprising that this month Gilead has announced the $11.9bn acquisition of Kite Pharma. ... In this case Gilead’s cash mountain and the pressing need for a deal outweighed the uncertainty

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Digital
Tools for the digital world
The next step for the pharma industry...
How Can We Make Payer Communications Really Sing?
With so many different influences at play in access decisions, how can we make sure we tap into what’s really driving payer decision-making. How do we go beyond the stated...
Harnessing the power of core elements to optimise market access
This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...

Infographics